

Results for announcement to the market		
AFT Pharmaceuticals Limited		
Reporting Period	6 months to September 30 2023	
Previous Reporting Period	6 months to September 30 2022	
Currency	NZ\$	
	Amount (000s)	Percentage change
Revenue from continuing operations	\$83,614	Up 27%
Total Revenue	\$83,614	Up 27%
Net operating profit/(loss) from continuing operations	\$3,250	Down 6%
Total operating net profit/(loss)	\$3,250	Down 6%
Net profit/(loss) after tax from continuing operations	\$1,816	Up 17%
Total Net profit/(loss) after tax	\$1,816	Up 17%
Interim/Final Dividend		
Quoted Equity Securities:		
Amount per Quoted Equity Security	\$0.01100000	
Imputed amount per Quoted Equity Security	No imputation	
Record Date	19/06/2023	
Dividend Payment Date	04/07/2023	
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security	\$0.23	\$0.21
A brief explanation of any of the figures above necessary to enable the figures to be understood	<p>Accompanying this announcement are the Group's unaudited consolidated financial statements for the six months ended 30 September 2023. These financial statements and the half year results commentary dated 23 November 2023 provide the balance of information requirements in accordance with NZX Listing Rule 3.5 and Appendix 2.</p> <p>Pursuant to ASX listing rule 1.15.3 AFT Pharmaceuticals Limited confirms that it continues to comply with the rules of its home exchange (NZX Main Board).</p>	
Authority for this announcement		
Name of person authorised to make this announcement	Malcolm Tubby	
Contact person for this announcement	Malcolm Tubby, Chief Financial Officer, AFT Pharmaceuticals Ltd	
Contact phone number	+64 9 488 0232	
Contact email address	malcolm.tubby@aftpharm.com	
Date of release through MAP	23 November 2023	

Unaudited financial statements accompany this announcement.